These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 24203056)
1. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Benitez JM; Meuwis MA; Reenaers C; Van Kemseke C; Meunier P; Louis E Gut; 2013 Dec; 62(12):1806-16. PubMed ID: 24203056 [TBL] [Abstract][Full Text] [Related]
2. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594 [TBL] [Abstract][Full Text] [Related]
3. Optimising monitoring in the management of Crohn's disease: a physician's perspective. Papay P; Ignjatovic A; Karmiris K; Amarante H; Milheller P; Feagan B; D'Haens G; Marteau P; Reinisch W; Sturm A; Steinwurz F; Egan L; Panés J; Louis E; Colombel JF; Panaccione R J Crohns Colitis; 2013 Sep; 7(8):653-69. PubMed ID: 23562672 [TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796 [TBL] [Abstract][Full Text] [Related]
5. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204 [TBL] [Abstract][Full Text] [Related]
6. Diagnosis and monitoring of postoperative recurrence in Crohn's disease. Yamamoto T Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):55-66. PubMed ID: 25030843 [TBL] [Abstract][Full Text] [Related]
7. Assessment of capsule endoscopy scoring index, clinical disease activity, and C-reactive protein in small bowel Crohn's disease. Yang L; Ge ZZ; Gao YJ; Li XB; Dai J; Zhang Y; Xue HB; Zhao YJ J Gastroenterol Hepatol; 2013 May; 28(5):829-33. PubMed ID: 23425203 [TBL] [Abstract][Full Text] [Related]
8. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases. Jung YS; Park JJ; Kim SW; Hong SP; Kim TI; Kim WH; Cheon JH Dig Liver Dis; 2012 Nov; 44(11):897-903. PubMed ID: 22721842 [TBL] [Abstract][Full Text] [Related]
9. Clinical perspectives in Crohn's disease. Objective measures of disease activity: alternatives to symptom indices. Loftus EV Rev Gastroenterol Disord; 2007; 7 Suppl 2():S8-S16. PubMed ID: 17392639 [TBL] [Abstract][Full Text] [Related]
10. Capsule endoscopy findings in patients with suspected Crohn's disease and biochemical markers of inflammation. De Bona M; Bellumat A; Cian E; Valiante F; Moschini A; De Boni M Dig Liver Dis; 2006 May; 38(5):331-5. PubMed ID: 16569524 [TBL] [Abstract][Full Text] [Related]
12. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360 [TBL] [Abstract][Full Text] [Related]
13. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH; Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483 [TBL] [Abstract][Full Text] [Related]
15. Inflammatory bowel diseases: controversies in the use of diagnostic procedures. Vucelic B Dig Dis; 2009; 27(3):269-77. PubMed ID: 19786751 [TBL] [Abstract][Full Text] [Related]
16. Faecal lactoferrin, capsule endoscopy and Crohn's disease. Is there a three way relationship? A pilot study. Sidhu R; Sanders DS; Wilson P; Foye L; Morley S; McAlindon ME J Gastrointestin Liver Dis; 2010 Sep; 19(3):257-60. PubMed ID: 20922188 [TBL] [Abstract][Full Text] [Related]
17. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Lönnkvist MH; Theodorsson E; Holst M; Ljung T; Hellström PM Scand J Gastroenterol; 2011 Apr; 46(4):420-7. PubMed ID: 21114432 [TBL] [Abstract][Full Text] [Related]
18. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Denis MA; Reenaers C; Fontaine F; Belaïche J; Louis E Inflamm Bowel Dis; 2007 Sep; 13(9):1100-5. PubMed ID: 17508418 [TBL] [Abstract][Full Text] [Related]
19. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392 [TBL] [Abstract][Full Text] [Related]
20. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Sipponen T; Kärkkäinen P; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M Aliment Pharmacol Ther; 2008 Nov; 28(10):1221-9. PubMed ID: 18752630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]